Terminated PHASE1 INTERVENTIONAL 1-arm NCT00508456

Dietary Methionine Restriction Plus Temozolomide for Recurrent GBM

A Phase I Study of Dietary Methionine Restriction and Temodar® (Temozolomide) for the Treatment of Recurrent and Progressive Glioblastoma Multiforme

Sponsor: M.D. Anderson Cancer Center

Conditions Glioblastoma Multiforme

Interventions Hominex-2 Temodar (Temozolomide)

Updated 5 times since 2017 Last updated: Jan 12, 2012 Started: Aug 31, 2004 Primary completion: Nov 30, 2008 Completion: Nov 30, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Low Accrual

Other terminated trials from M.D. Anderson Cancer Center

See all terminations from M.D. Anderson Cancer Center

Other Glioblastoma Multiforme trials with similar outcome

Browse all Glioblastoma Multiforme trials

A PHASE1 clinical study on Glioblastoma Multiforme, this trial is terminated or withdrawn. The trial is conducted by M.D. Anderson Cancer Center and has accumulated 5 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE1
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE1
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE1

First recorded

Aug 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

M.D. Anderson Cancer Center

Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States